{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:28:44Z","timestamp":1785810524670,"version":"3.56.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007352","name":"Staatssekretariat f\u00fcr Bildung, Forschung und Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007352","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jclinepi.2025.111827","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T19:17:23Z","timestamp":1746818243000},"page":"111827","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Characteristics, design, and statistical methods in platform trials: a systematic review"],"prefix":"10.1016","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-9668","authenticated-orcid":false,"given":"Cl\u00e9ment R.","family":"Massonnaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9856-3500","authenticated-orcid":false,"given":"Christof Manuel","family":"Sch\u00f6nenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2498-0467","authenticated-orcid":false,"given":"Malena","family":"Chiaborelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-9050","authenticated-orcid":false,"given":"Selina","family":"Ehrenzeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3726-1856","authenticated-orcid":false,"given":"Alexandra","family":"Griessbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Gillibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2070-5230","authenticated-orcid":false,"given":"Matthias","family":"Briel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3681-6314","authenticated-orcid":false,"given":"C\u00e9dric","family":"Laou\u00e9nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jclinepi.2025.111827_bib1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.2015.2316","article-title":"The platform trial: an efficient strategy for evaluating multiple treatments","volume":"313","author":"Berry","year":"2015","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111827_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/1740774515626362","article-title":"Efficiencies of platform clinical trials: a vision of the future","volume":"13","author":"Saville","year":"2016","journal-title":"Clin Trials"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111827_bib3","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cpt.514","article-title":"PIPELINEs: creating comparable clinical knowledge efficiently by linking trial platforms","volume":"100","author":"Trusheim","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.111827_bib5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s13063-019-3377-5","article-title":"Mind the gap? The platform trial as a working environment","volume":"20","author":"Morrell","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib7","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s13063-019-3216-8","article-title":"This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols","volume":"20","author":"Schiavone","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.jclinepi.2025.111827_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2020.04.025","article-title":"An overview of platform trials with a checklist for clinical readers","volume":"125","author":"Park","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111827_bib9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.molonc.2015.02.011","article-title":"The Brave New World of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research","volume":"9","author":"Berry","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/1745-6215-13-168","article-title":"Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial","volume":"13","author":"Sydes","year":"2012","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111827_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1464-410X.2008.07583.x","article-title":"Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer","volume":"102","author":"Langley","year":"2008","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/clpt.2009.68","article-title":"I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy","volume":"86","author":"Barker","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.111827_bib13","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJMe2025674","article-title":"The RECOVERY platform","volume":"384","author":"Normand","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111827_bib14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1513\/AnnalsATS.202003-192SD","article-title":"The REMAP-CAP (randomized embedded multifactorial adaptive platform for community-acquired pneumonia) study. Rationale and design","volume":"17","author":"Angus","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111827_bib15","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111827_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with covid-19","volume":"385","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111827_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.7326\/M21-1269","article-title":"Accelerating COVID-19 therapeutic interventions and vaccines (ACTIV): designing master protocols for evaluation of candidate COVID-19 therapeutics","volume":"174","author":"LaVange","year":"2021","journal-title":"Ann Intern Med"},{"issue":"Supplement_2","key":"10.1016\/j.jclinepi.2025.111827_bib18","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1093\/infdis\/jiad246","article-title":"ACTIV-2: a platform trial for the evaluation of novel therapeutics for the treatment of early COVID-19 in outpatients","volume":"228","author":"Currier","year":"2023","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.111827_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing monoclonal antibody for hospitalized patients with covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jclinepi.2025.111827_bib20","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S2213-2600(23)00147-9","article-title":"Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial","volume":"11","author":"Brown","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"14","key":"10.1016\/j.jclinepi.2025.111827_bib21","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jama.2023.3546","article-title":"Renin-angiotensin system modulation with synthetic angiotensin (1-7) and angiotensin II type 1 receptor\u2013biased ligand in adults with COVID-19: two randomized clinical trials","volume":"329","author":"Self","year":"2023","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.jclinepi.2025.111827_bib22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jclinepi.2025.111827_bib23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/M22-3350","article-title":"Effect of thromboprophylaxis on clinical outcomes after COVID-19 hospitalization","volume":"176","author":"Wang","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2025.111827_bib24","article-title":"Inhaled fluticasone for outpatient treatment of covid-19: a decentralized, placebo-controlled, randomized, platform clinical trial","author":"Naggie","year":"2022","journal-title":"medRxiv [Preprint]"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib25","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s13063-019-3664-1","article-title":"Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols","volume":"20","author":"Park","year":"2019","journal-title":"Trials"},{"issue":"7","key":"10.1016\/j.jclinepi.2025.111827_bib26","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.clinthera.2020.05.010","article-title":"The evolution of master protocol clinical trial designs: a systematic literature review","volume":"42","author":"Meyer","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.jclinepi.2025.111827_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2023.02.010","article-title":"Methodology and design of platform trials: a meta-epidemiological study","volume":"157","author":"Pitre","year":"2023","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111827_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.3109","article-title":"Characteristics, progression, and output of randomized platform trials: a systematic review","volume":"7","author":"Griessbach","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111827_bib29","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cpt.1804","article-title":"Current statistical considerations and regulatory perspectives on the planning of confirmatory basket, umbrella, and platform trials","volume":"107","author":"Collignon","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111827_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/cpt.1908","article-title":"Potential statistical issues between designers and regulators in confirmatory basket, umbrella, and platform trials","volume":"108","author":"Berry","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib31","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/pst.2059","article-title":"Controlling type I error rates in multi-arm clinical trials: a case for the false discovery rate","volume":"20","author":"Wason","year":"2021","journal-title":"Pharm Stat"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib32","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13063-021-05150-7","article-title":"Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats","volume":"22","author":"Lee","year":"2021","journal-title":"Trials"},{"issue":"16","key":"10.1016\/j.jclinepi.2025.111827_bib33","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1056\/NEJMc2102446","article-title":"Platform trials \u2014 beware the noncomparable control group","volume":"384","author":"Dodd","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12874-022-01683-w","article-title":"On model-based time trend adjustments in platform trials with non-concurrent controls","volume":"22","author":"Roig","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111827_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/cpt.2183","article-title":"Collaborative platform trials to fight COVID-19: methodological and regulatory considerations for a better societal outcome","volume":"110","author":"Collignon","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.jclinepi.2025.111827_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003583","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"18","author":"Page","year":"2021","journal-title":"PLOS Med"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111827_bib38","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/17407745221110880","article-title":"A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats","volume":"19","author":"Longini","year":"2022","journal-title":"Clin Trials Lond Engl"},{"key":"10.1016\/j.jclinepi.2025.111827_bib39","series-title":"Abstracts of Poster and E-Poster Presentations","first-page":"A79.2","article-title":"PA-424 the INTEGRATE study: an adaptive platform trial for the development of new interventions to combat Lassa Fever in West Africa","author":"Jaspard","year":"2023"},{"issue":"18","key":"10.1016\/j.jclinepi.2025.111827_bib40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000200604","article-title":"Designing multi-arm multistage adaptive trials for neuroprotection in progressive multiple sclerosis","volume":"98","author":"Li","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jclinepi.2025.111827_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jclinepi.2022.05.014","article-title":"A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols","volume":"149","author":"Sch\u00f6nenberger","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"10457","key":"10.1016\/j.jclinepi.2025.111827_bib42","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0140-6736(24)01295-9","article-title":"Bayesian statistics for clinical research","volume":"404","author":"Goligher","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jclinepi.2025.111827_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078711","article-title":"REMAP Periop: a randomised, embedded, multifactorial adaptive platform trial protocol for perioperative medicine to determine the optimal enhanced recovery pathway components in complex abdominal surgery patients within a US healthcare system","volume":"13","author":"Holder-Murray","year":"2023","journal-title":"BMJ Open"},{"issue":"11","key":"10.1016\/j.jclinepi.2025.111827_bib44","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/cid\/ciac476","article-title":"The Staphylococcus aureus network adaptive platform trial protocol: new tools for an old foe","volume":"75","author":"Tong","year":"2022","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"8","key":"10.1016\/j.jclinepi.2025.111827_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069176","volume":"13","author":"Gbinigie","year":"2023","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.jclinepi.2025.111827_bib47","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/infdis\/jiad275","article-title":"Clinical antiviral efficacy of remdesivir in coronavirus disease 2019: an open-label, randomized controlled adaptive platform trial (PLATCOV)","volume":"228","author":"Jittamala","year":"2023","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111827_bib48","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.2010.31.1423","article-title":"Outcome-adaptive randomization: is it useful?","volume":"29","author":"Korn","year":"2011","journal-title":"J Clin Oncol"},{"issue":"463","key":"10.1016\/j.jclinepi.2025.111827_bib49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1198\/016214503000000576","article-title":"Optimality, variability, power: evaluating response-adaptive randomization procedures for treatment comparisons","volume":"98","author":"Hu","year":"2003","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111827_bib50","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/1740774509350327","article-title":"Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit","volume":"6","author":"Lachin","year":"2009","journal-title":"Clin Trials"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111827_bib51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/sim.2763","article-title":"A 25-year review of sequential methodology in clinical studies","volume":"26","author":"Todd","year":"2007","journal-title":"Stat Med"},{"issue":"19","key":"10.1016\/j.jclinepi.2025.111827_bib52","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1002\/sim.2455","article-title":"Operating characteristics of sample size re-estimation with futility stopping based on conditional power","volume":"25","author":"Lachin","year":"2006","journal-title":"Stat Med"},{"issue":"18","key":"10.1016\/j.jclinepi.2025.111827_bib53","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/sim.2151","article-title":"A review of methods for futility stopping based on conditional power","volume":"24","author":"Lachin","year":"2005","journal-title":"Stat Med"},{"issue":"13-14","key":"10.1016\/j.jclinepi.2025.111827_bib54","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/sim.4780131308","article-title":"Interim analysis: the alpha spending function approach","volume":"13","author":"Demets","year":"1994","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111827_bib55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0197-2456(91)90120-B","article-title":"The choice of sequential boundaries based on the concept of power spending","volume":"12","author":"Bauer","year":"1991","journal-title":"Control Clin Trials"},{"issue":"6","key":"10.1016\/j.jclinepi.2025.111827_bib56","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/sim.4780100609","article-title":"Multiple testing in clinical trials","volume":"10","author":"Bauer","year":"1991","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.jclinepi.2025.111827_bib57","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1177\/0962280215595058","article-title":"A Bayesian sequential design using alpha spending function to control type I error","volume":"26","author":"Zhu","year":"2017","journal-title":"Stat Methods Med Res"},{"issue":"2","key":"10.1016\/j.jclinepi.2025.111827_bib58","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1214\/18-BA1109","article-title":"Control of type I error rates in bayesian sequential designs","volume":"14","author":"Shi","year":"2019","journal-title":"Bayesian Anal"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib59","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12874-020-01042-7","article-title":"Do we need to adjust for interim analyses in a Bayesian adaptive trial design?","volume":"20","author":"Ryan","year":"2020","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jclinepi.2025.111827_bib60","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12874-019-0892-8","article-title":"Comparison of Bayesian and frequentist group-sequential clinical trial designs","volume":"20","author":"Stallard","year":"2020","journal-title":"BMC Med Res Methodol"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562500160X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089543562500160X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:34:37Z","timestamp":1755650077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089543562500160X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":58,"alternative-id":["S089543562500160X"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111827","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics, design, and statistical methods in platform trials: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2025.111827","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111827"}}